Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Sanhome was one of the first group of companies which have been awarded GMP certificate in China. The company has been certificated as ‘state high-tech innovation enterprise’ by China Ministry of Science & Technology in 2003, has been ranked in top 100 pharmaceutical enterprises in China since 2009, and has been awarded ‘Top 100 pharmaceutical enterprises’ and ‘Top 50 pharmaceutical enterprises in growth’ by All-China Federation of Industry & Commerce in 2015.

APEIRON is a focused on the discovery and development of novel cancer immunotherapies. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhanc immune reactivity via an intracellular immune master checkpoint, Cbl-b. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

OnQuality Pharmaceuticals offers trials to assess the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Nanjing Mingde New Drug Research and Development Co., Ltd., established on 2011-12-16, The scope of business includes engaging in pharmaceutical,Biological product,medical instruments,food development,Research;Environmental and pesticide testing services;Pharmaceutical Small Molecule Compound Library,Preclinical studies of drug leads and drug products,Technology development related to process development and clinical research,Technology introduction,Technical Services,Technical consulting and technology transfer,related technology,Licensing of Patents and Intellectual Property,Achievement Transformation and Transfer;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval)

At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

SCARLETRED is an international Digital Health Scaleup revolutionising the global skin care market by the AI powered SCARLETRED®VISION platform system. The problem we solved is subjective skin assessment and lacking standardization in Dermatology. Our medical device certified platform is fully mobile, runs via mobile App on smartphones and connects to our web platform, which enables to generate smart imaging data and novel AI decision support applications in Dermatology and Telemedicine. The multi award winning technology is supplied international via SaaS to Biopharma and Cosmetics Industry, Hospitals and Medical Experts. Protected via worldwide patents it facilitates standardized skin documentation and remote tracking of skin changes and therapeutic effects via mobile App. Images can be uploaded in a cloud based platform and objectively analysed for visual skin changes over time, such as for allergic reactions, pigmentation changes, acne, psoriasis, disease or wound healing. SCARLETRED provides services on a broad range of dermatologic conditions ranging from B2B to B2B2C applications.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Jiangsu Desano Pharmaceutical Co. Ltd. is a Chinese private company located in Liyang. The firm provides pharmaceutical preparation services.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Hunan Eurasia Pharmaceutical Co., Ltd., established on 2007-11-22, Business scope includes chemical reagents and auxiliaries(Monitor Chemicals,Excluding hazardous chemicals)manufacturing,Sales;Manufacture of chemical raw materials;Production of disinfection products;Class I medical device,Class II medical device,Class III Medical Devices,Wholesale of chemical raw materials;Chemical Engineering Research Services;Chemical Products,Biological product,drug development;disinfectant,Sanitation products,Drug inspection and testing equipment sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Ximai Pharmaceutical Technology Co., Ltd., established on 2010-06-08, The scope of business includes engaging in chemical synthesis,Biotechnology,Pharmaceutical Intermediates,food additives,Technical consulting in the field of pharmaceutical preparations,technology development,technology transfer,Technical Services,business inquiries(In addition to brokerage),Office Supplies,Sales of daily necessities,Pre-packaged food(With freezer,Does not contain cooked food lo mei,The operating permit)Wholesale Non-Physical Ways,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Guangzhou Keqing New Drug Development Co., Ltd., established on 2013-03-13, Business scope includes biotechnology consulting,communication service;Biotechnology Development Services;Biotechnology Transfer Services;Medical Research and Experimental Development;Biotechnology Extension Services;

Shanghai Xiaowu Pharmaceutical Technology Co., Ltd., established on 2017-11-06, The scope of business includes engaging in medical technology,Technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.